Oral semaglutide vs orforglipron: what ORION’s indirect comparison tells clinicians and patients now
The ORION analysis from Novo Nordisk used population-adjusted indirect comparison methods to contrast oral semaglutide 25 mg tablets with Eli…
Petrelintide in Genentech’s Phase II ZUPREME-1 Trial: Meaningful Weight Loss, Slower Titration, and What Still Needs Proof
Genentech’s Phase II ZUPREME-1 trial suggests petrelintide is not a quick fix, but it may become a useful long-term obesity…
CagriSema’s REDEFINE 4 Trial: What Its Findings Signal for Obesity Treatment Constraints
Impact of CagriSema’s Trial Results Novo Nordisk’s CagriSema has faced a significant setback by failing to meet its primary endpoint…